Table 6 Distribution of patients with SLE flare
| Â | Pulmonary hypertension | Serositis | Anemia associated with SLE | |||
|---|---|---|---|---|---|---|
Yes (N = 20) | No (N = 101) | Yes (N = 35) | No (N = 86) | Yes (N = 50) | No (N = 71) | |
Age (Year), mean (SD) | 41.3(11.8) | 39.7(13.4) | 37.7(12.7) | 40.9(12.3) | 37.6(13.8) | 41.6(12.5) |
Gender (female/male) | 20/0 | 93/8 | 34/1 | 79/7 | 47/3 | 66/5 |
Disease duration (Month), mean (SD) | 109.6(79.5) | 89.9(80.2) | 93.1(85.3) | 93.2(78.4) | 86.3(71.1) | 98.0(86.0) |
SLEDAI-2 K,mean (SD) | 12.1(8.0) | 11.8(5.9) | 15.2(5.5) | 10.5(6.1) | 14.4(5.8) | 10.1(5.9) |
Initial treatment | ||||||
 Glucocorticoid amount (mg/kg/d), mean (SD) | 0.80(0.22) | 0.95(0.97) | 0.89(0.34) | 0.94(1.04) | 0.88(0.37) | 0.96(1.13) |
 Hydroxychloroquine, n (%) | 18(90.0) | 80(79.2) | 30(85.7) | 68(79.1) | 43(86.0) | 55(77.5) |
Immunosuppressive therapy, n (%) | 7(35.0) | 42(41.6) | 12(34.3) | 37(43.0) | 19(38.0) | 30(42.3) |
 Regular maintenance treatment, n (%) | 3(15.0) | 53(52.5) | 9(25.7) | 47(54.7) | 14(28.0) | 42(59.2) |
 maintenance therapy < 1 year, n (%) | 6(30.0) | 14(13.9) | 9(25.7) | 11(12.8) | 7(14.0) | 13(18.3) |
 maintenance therapy < 2 years, n (%) | 8(40.0) | 20(19.8) | 11(31.4) | 17(19.8) | 11(22.0) | 17(23.9) |
 maintenance therapy < 3 years, n (%) | 9(45.0) | 25(24.8) | 12(34.3) | 22(25.6) | 13(26) | 21(29.6) |
 maintenance therapy < 4 years, n (%) | 14(70.0) | 84(83.2) | 27(77.1) | 71(82.6) | 41(82.0) | 57(80.3) |
 maintenance therapy < 5 years, n (%) | 15(75.0) | 86(85.1) | 29(82.9) | 72(83.7) | 43(86.0) | 58(81.7) |